Clinical Trial Update: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) [Phase 1]

View source ↗

Summary

An early-phase clinical trial evaluating Tagraxofusp as post-transplant maintenance in patients with CD123-positive acute myeloid leukemia, myelodysplastic synd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelofibrosis
• Myelomonocytic Leukemia

Drugs mentioned

• Tagraxofusp (tagraxofusp)

Snippet

Sponsor: Karen Ballen, MD | Conditions: Myelofibrosis, Chronic Myelomonocytic Leukemia | Phase 1 | Status: RECRUITING